A National Registry on Chinese Patients With Cystic Fibrosis

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Mar 13, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding cystic fibrosis (CF) in Chinese patients. CF is a rare disease that primarily affects the lungs and digestive system, and it is typically more common in Caucasians. However, there is limited information about CF among the large population in China. The main goals of this study are to find out how many people in China have CF, how the disease affects them, how it is diagnosed and treated, and to assess the overall quality of care and health outcomes for these patients.

To join this study, participants must meet certain criteria. They should have been diagnosed with CF according to specific guidelines, be in a stable health condition without lung infections for at least four weeks, and their guardians must provide consent if they are minors. Unfortunately, patients with other related lung diseases or severe heart or kidney conditions cannot participate. Those who join the study can expect to provide important information that will help improve understanding and care for CF in China, contributing to better health outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.
• Exclusion Criteria:
• • Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease